Drug intelligence / Profile preview

Ganyan-1

Development stage: Preclinical
Lead developer: Gan & Lee Pharmaceuticals
Administration: Oral

Overview

**Ganyan-1** is an investigational multi-herb Chinese herbal granule formulation being studied for dry eye disease by Beijing Tongren Hospital. In the registered randomized trial, the formulation comprises Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and goji berries; it is administered orally as 10 g granules twice daily for four weeks, alongside sodium hyaluronate eye drops in the active treatment arm. Its molecular composition, pharmacologically active constituents, and defined target-level mechanism have not been publicly specified.

Other names: Ganyan1Ganyan-1Ganyan 1

Beyond the preview

Go deeper on Ganyan-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganyan-1.

Explore the full profile